Zydus Lifesciences and Lupin have forged a strategic partnership to market Saroglitazar Mg, a breakthrough drug for Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato Hepatitis (NASH) in India. Lupin will have semi-exclusive rights to co-market the drug as LINVAS.